These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28149783)

  • 1. Efficacy and safety of ranibizumab for wet age-related macular degeneration in Chinese patients.
    Qi HJ; Li XX; Zhang JY; Zhao MW
    Int J Ophthalmol; 2017; 10(1):91-97. PubMed ID: 28149783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optical Coherence Tomography Angiography-based Follow-up Observation of Wet Age-related Macular Degeneration after Intravitreal Anti-Ranibizumab Therapy].
    Yuan MZ; Zhou HY; Chen YX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Jun; 41(3):359-366. PubMed ID: 31282330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study.
    Banister K; Cook JA; Scotland G; Azuara-Blanco A; Goulão B; Heimann H; Hernández R; Hogg R; Kennedy C; Sivaprasad S; Ramsay C; Chakravarthy U
    Health Technol Assess; 2022 Jan; 26(8):1-142. PubMed ID: 35119357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
    Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
    Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
    Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
    Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment.
    Zhao C; Zhang Z; Chen L; Wang F; Xu D
    Med Sci Monit; 2016 Mar; 22():833-9. PubMed ID: 26972376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
    Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
    Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial utilization of aflibercept in exudative age-related macular degeneration.
    Cho H; Weber ML; Shah CP; Heier JS
    Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.
    Rouvas A; Petrou P; Vergados I; Pechtasides D; Liarakos V; Mitsopoulou M; Ladas I
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1609-16. PubMed ID: 19609550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
    Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
    Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.